Brad Mills, who has played 34 NHL games with Chicago and New Jersey and is playing for Binghamton of the American League this year, tested positive for a performance-enhancing drug and was hit with a significant suspension.
The American Hockey League announced Tuesday a 20-game suspension for Binghamton Senators Brad Mills after he tested positive for a performance-enhancing drug.
The 31-year-old Mills, who had one goal and two points in 34 games of NHL experience with the New Jersey Devils and Chicago Blackhawks, was in his first year in Binghamton after an eight-year AHL career that included stops in Lowell, Albany and Rockford; he has already sat out four games after the Senators removed him from the lineup last week once the test result came in, and he’s eligible to return to the lineup Dec. 12.
Mills, a former team MVP at Yale University in 2003-04, has already apologized through the Professional Hockey Players’ Association for the failed test, which is now administered by the same doctors who supervise the NHL/NHL Players’ Association’s performance-enhancing substances program and substance abuse program. The AHL did not disclose what substance Mills tested positive for, but the bigger concern for him is failing another test: in accordance with AHL policy, a second failed test – all of which are randomly administered to players – will result in a 60-game suspension, and a third failed test results in the player being banned for life (with the chance to apply for reinstatement in two years).